Field Medical Director
Job Title: Field Medical Director (FMD)
Reports to: Sr. Director, Medical Affairs
The FMD is a field-based, non-promotional medical and scientific role. The FMD’s key objective is to engage scientifically with HCPs and medical experts to carry out the relevant medical strategic and tactical plans. The FMD must demonstrate deep therapeutic area expertise and collaborate effectively with cross-functional colleagues and execute all relevant activities in alignment with regulatory, ethical and compliance guidelines. This role will report directly to the Sr. Director, Medical Affairs.
Principal Duties and Responsibilities:
The following is a summary of the significant functions of this individual's job. They may perform other duties, both major and minor, which are not mentioned below, and specific services may change from time to time. Customer engagements may include but not be limited to:
- Emerging data discussions and presentations
- Exploration of areas of unmet medical need
- Clinical trial activities and pipeline discussions
- Capture of medical insights, responding to unsolicited requests
- Disease, product and drug safety education.
- Responsible for establishing relationships and engaging in peer -to-peer level scientific discussions around emerging data, treatment guidelines, molecular pathways, FCR001 mechanism of action (MOA)
- Implementing scientific and educational strategies in collaboration with colleagues from Medical Affairs and Clinical Operations to support Talaris-sponsored trials
- Attend and support Advisory Boards and Congresses
- Performs other duties as assigned
Minimum Education, Training, and Experience Required:
- Cell Therapy or Stem Cell Transplant experience required
- Advanced degree required; PharmD, PhD, MD (medical degree preferred)
- Minimum of 3 years of Field Medical Affairs preferred
- Detailed knowledge of clinical medicine, disease management, and medical research is necessary, clinical research as well as proven knowledge of GCP practices and standards.
- Biotech / Pharmaceutical industry experience preferred.
- Possess a thorough understanding of the FDA, OIG, HIPPA, PhRMA Code and other ethical guidelines relevant to the pharmaceutical industry, to ensure compliance with these external as well as internal guidelines and standard operating procedures.
- Have the ability to gain medical insights, uncover business opportunities for Talaris and leverage internal resources to meet customer needs aligned with Talaris strategy
- Must be a strong team player who can effectively work cross-functionally in a matrix environment, including collaboration with clinical and commercial personnel as necessary.
- Prolonged periods of sitting at a desk and working on a computer.
- Health insurance
- Dental insurance
- Vision insurance
- Paid time off 25 days
- Stock Options
Talaris Therapeutics, Inc. (“Talaris”) is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Achieving durable, drug-free immune tolerance to a donated organ has been referred to as a “Holy Grail” of organ transplant. In a ground-breaking, phase 2 study conducted between 2009 – 2016, our lead therapy, FCR001, enabled 70% of living donor kidney transplant recipients to be weaned off all immunosuppression within 12 months of their kidney transplant, without rejecting their donated organ. The benefits of our therapy have been shown to be extremely durable. We have followed these patients for an average of over five years since their transplant, and the longest for over ten years, and not a single patient who was tolerized in our phase 2 study has subsequently had to resume immunosuppression. Since late-2018, Talaris has raised over $190M in private financing from leading life sciences investors and has initiated a Phase 3 registration trial of our therapy in living donor kidney transplant patients. In 2021, the company also plans to initiate Phase 2 trials of FCR001 in scleroderma as well as in patients who have previously received a living donor kidney transplant. Our cell processing facility is based in Louisville, KY, and we have a corporate office in Boston, MA